23 results
424B3
CHRO
Chromocell Therapeutics Corp.
15 May 24
Prospectus supplement
4:21pm
, projected future taxable income, and taxable income in carryback years and tax-planning strategies when making this assessment. There is currently
424B3
CHRO
Chromocell Therapeutics Corp.
15 May 24
Prospectus supplement
4:15pm
, projected future taxable income, and taxable income in carryback years and tax-planning strategies when making this assessment. There is currently
10-Q
2024 Q1
CHRO
Chromocell Therapeutics Corp.
15 May 24
Quarterly report
4:06pm
-planning strategies when making this assessment. There is currently significant negative evidence which contributes to our recording a valuation allowance
424B3
CHRO
Chromocell Therapeutics Corp.
16 Apr 24
Prospectus supplement
5:49pm
Healthy Subjects with Food Effect Assessment
SAD/MAD
SAD: 30, 120, 300, 600, 1200, 1800, or 2400 mg QD on Day 1.
MAD: 120, 300, 600, 1200, 1800 or 2400 … Effect Assessment
Cross-over
200 mg Melt Granulation Capsule (fed and fasted) vs 200 mg Suspension Capsule (fasted)
Healthy
Volunteers
July 31, 2017
424B3
CHRO
Chromocell Therapeutics Corp.
16 Apr 24
Prospectus supplement
5:45pm
Healthy Subjects with Food Effect Assessment
SAD/MAD
SAD: 30, 120, 300, 600, 1200, 1800, or 2400 mg QD on Day 1.
MAD: 120, 300, 600, 1200, 1800 or 2400 … Effect Assessment
Cross-over
200 mg Melt Granulation Capsule (fed and fasted) vs 200 mg Suspension Capsule (fasted)
Healthy
Volunteers
July 31, 2017
10-K
r4hwmmy 6ttegoxvun
16 Apr 24
Annual report
4:48pm
424B4
467hw
20 Feb 24
Prospectus supplement with pricing info
5:30pm
424B4
82wecwp2pdjq7qw8jal1
20 Feb 24
Prospectus supplement with pricing info
5:28pm
CORRESP
op7nc45elutbe
30 Jan 24
Correspondence with SEC
12:00am